Cadila Pharma launches Belmore to treat uncontrolled LDL-cholesterol. High LDL cholesterol can lead to serious life-threatening heart complications due to blockage in blood vessels. More than 30 % of adults
ThRabis® is the world’s 1st novel three-dose rabies vaccine launched by Cadila Pharma. Aiming at a Rabies-Free India the recombinant nanoparticle-based rabies G protein vaccine is prepared using Virus-Like Particle
Cadila Pharma receives licence from MPP for generic version of Pfizer’s Covid-19 oral antiviral – nirmatrelvir. The drug is approved or under emergency use authorization for COVID-19 in many countries,
Cadila Pharmaceuticals expands oncology portfolio with Launch of Tarzed (Trastuzumab 440 Mg Injection). Tarzed is a humanized monoclonal antibody, recommended in HER2 Positive Early Breast cancer and Metastatic Breast Cancer.
Cadila pharmaceuticals launches Tikacad® an antiplatelet drug containing Ticagrelor, a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients. Ahmedabad: Cadila Pharmaceuticals
Sepsivac® from Cadila Pharmaceuticals wins ‘Excellence in Packaging Design’ award at India packaging awards. Ahmedabad: Cadila Pharmaceuticals’ latest innovation for Sepsis treatment, Sepsivac®, recently won the India Packaging Award under
Cadila pharmaceuticals launches Obetocad, a generic Obeticholic Acid (Ocaliva®) in the liver therapy. Cadila is amongst the first brands to launch generic Obeticholic Acid(Ocaliva®), in India. The molecule is used
Cadila Pharma leads in digital transformation. The digital transformation has added a new dimension to the healthcare industry as till a while ago, digital was seen as the future, but
Cadila Pharmaceuticals launches Cadalimab™(Adalimumab biosimilar) for India. Adalimumabis a disease-modifying antirheumatic drug and a monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many
